Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Autolus Therapeutics plcNASDAQ: AUTL

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables declines year over year

Q1 FY2026 accounts receivables of $3.63M (cash outflow) fell 74.7% year over year, behind the -6.1% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 32.0% of revenue in FY2025, up 32.0 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -74.7% toward the trailing-twelve-month pace of -6.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.63M-142.4% QoQ
Last fiscal yearDec 2025
-$24.21M— YoY
LTMMar 2026
-$13.46M-6.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.7%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(24.21M) USD
Year-over-year change
—

Accounts Receivables vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 accounts receivables of $13.46M is the 2nd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -6.1% is the 3rd highest of 7, against a peer median of -61.9%.
  • Accounts receivables amounts to 14.5% of revenue for AUTL, versus a peer median of 9.2%.
AUTL Competitors Peer median
Accounts Receivables for AUTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$125.44M +174128.2%—9.2%
AUTLAutolus Therapeutics plcLTM Mar 2026$13.46M -6.1%—14.5%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$8.88M -67.1%—38.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026$5.47M -147.5%—12.1%
CLLSCellectis S.A.LTM Mar 2026$2.24M -96.4%-20.9%3.3%
FATEFate Therapeutics, Inc.LTM Mar 2026$1.7M +279.7%—26.9%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$378K -56.7%-57.2%3.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 ——0.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 ———
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding AUTL) $0-61.9%-39.0%9.2%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(287.53M)
Depreciation & Amortization8.46M7.42M6.57M7.72M9.81M
Deferred Income Tax(72K)(268K)(986K)(185K)(286K)
Stock-Based Compensation9.94M12.01M11.2M15.47M14.44M
Change in Working Capital4.14M3.97M292K(23.66M)(52.11M)
Accounts Receivables0000(24.21M)
Inventory000(4.23M)(40.34M)
Accounts Payables(1.82M)22K(509K)1.59M1.3M
Other Working Capital5.95M3.95M801K(21.02M)11.14M
Other Non-Cash Items1.77M13.4M45.72M15.04M32.1M
Operating Cash Flow(117.86M)(112.31M)(145.59M)(206.27M)(283.57M)
Capital Expenditures(8.86M)(10.84M)(10.99M)(34.82M)(27.13M)
Acquisitions (Net)00000
Purchases of Investments000(359.73M)(242.62M)
Sales of Investments0000428.21M
Other Investing Activities000(12.74M)(8.09M)
Investing Cash Flow(8.86M)(10.84M)(10.99M)(394.55M)158.46M
Debt Repayment00000
Common Stock Issued245.9M163.85M0549.98M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities38.16M59.76M(883K)39.58M(4.34M)
Financing Cash Flow284.06M223.61M(883K)589.55M(4.34M)
Effect of Forex Changes(754K)(28.38M)15.03M(261K)6.28M
Net Change in Cash156.59M72.09M(142.43M)(11.53M)(123.17M)
Free Cash Flow(126.72M)(123.15M)(156.57M)(241.09M)(310.7M)

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.